Yahoo Web Search

Search results

1. www.ft.com › content › d2dfc0c4-85e0-4cf5-b926-c10dRoche cuts drug pipeline in effort to revitalise business

   www.ft.com › content › d2dfc0c4-85e0-4cf5-b926-c10d

   • Cached

   Apr 24, 2024 · Roche has cut a fifth of its drug pipeline in six months, shedding prospective cancer and neurology treatments as the Swiss company seeks to revitalise its business under new chief...

2. www.reuters.com › business › healthcareRoche warns 2023 profits will fall on $5 bln COVID sales hit

   www.reuters.com › business › healthcare

   Feb 2, 2023 · Roche warned on Thursday profits will decline in 2023 as falling demand for its COVID-19 therapy and diagnostics kits will knock sales by over $5 billion, the latest sign that the...

3. www.reuters.com › breakingviews › roches-7-bln-dealRoche's $7 bln deal is pricey and partial cure | Reuters

   www.reuters.com › breakingviews › roches-7-bln-deal

   Oct 23, 2023 · Roche is eager to restock its pipeline after a dementia drug reported disappointing results last year. But the latest deal is small in the scope of the overall company.

4. www.bloomberg.com › news › articlesRoche Disappoints With Cautious Forecast as Revenue Declines ...

   www.bloomberg.com › news › articles

   • Cached

   Oct 19, 2023 · Roche Holding AG fell the most in almost a year on Thursday after failing to deliver the forecast upgrade investors had hoped to get.

5. www.reuters.com › business › healthcareRoche shares fall on modest 2024 outlook | Reuters

   www.reuters.com › business › healthcare

   Feb 1, 2024 · The company said its results showed it was overcoming a slump in demand for its COVID-19 products and a decline in sales of a trio of established cancer drugs.

6. finance.yahoo.com › news › roche-forecasts-returnRoche shares fall on modest 2024 outlook - Yahoo Finance

   finance.yahoo.com › news › roche-forecasts-return

   • Cached

   Feb 1, 2024 · The company said its results showed it was overcoming a slump in demand for its COVID-19 products and a decline in sales of a trio of established cancer drugs.

7. People also ask

   Why did Roche's shares fall?

   • Roche's shares fell during its third-quarter earnings when it did not raise 2023 sales guidance from a low-single digit rise. Schinecker, who took over as CEO in March 2023, mentioned that a strong Swiss franc weighed on the value of overseas sales. During the fourth quarter, the U.S dollar was about 8% lower than a year earlier on average against the franc.

   Roche shares fall on modest 2024 outlook | Reuters

   www.reuters.com/business/healthcare-pharmaceuticals/roche-forecasts-return-growth-2024-it-overcomes-drop-covid-sales-2024-02-01/

   See all results for this question

   Why did Roche stock fall 4% on Thursday?

   • Roche shares fell more than 4% on Thursday due to the market's disappointment with the company's more modest than expected 2024 outlook.

   Roche shares fall on modest 2024 outlook | Reuters

   www.reuters.com/business/healthcare-pharmaceuticals/roche-forecasts-return-growth-2024-it-overcomes-drop-covid-sales-2024-02-01/

   See all results for this question

   Why did Roche Holding AG fall the most in a year?

   • Roche Holding AG fell the most in almost a year on Thursday after failing to deliver the forecast upgrade investors had hoped to get. The stock declined as much as 5.1% in Zurich trading after the Swiss drugmaker reported declining quarterly revenue.

   Roche Disappoints With Cautious Forecast as Revenue Declines - Bloom…

   www.bloomberg.com/news/articles/2023-10-19/roche-sales-drop-as-new-drugs-don-t-make-up-for-covid-slump

   See all results for this question

   Why has Roche been penalized by investors since April 2022?

   • Since April 2022, Roche has been negatively impacted by investors due to the reduction of Covid-related activity and the publication of lower-than-expected results. The lack of significant positive indications on the new drugs trials also weighed on the stock price.

   Roche: The Recent Sell-Off Created A 30% Upside Potential

   seekingalpha.com/article/4669357-roche-recent-sell-off-30-percent-upside-potential

   See all results for this question

8. seekingalpha.com › article › 4669357-roche-recentRoche: The Recent Sell-Off Created A 30% Upside Potential

   seekingalpha.com › article › 4669357-roche-recent

   Feb 11, 2024 · Despite recent challenges, Roche's 2024 guidance shows potential for mid-single digit growth in revenues and EPS. Find out why RHHBY stock is a Buy.